Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Eledon Pharmaceuticals Inc (ELDN)

Eledon Pharmaceuticals Inc (ELDN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 243,138
  • Shares Outstanding, K 59,739
  • Annual Sales, $ 0 K
  • Annual Income, $ -40,330 K
  • EBIT $ -56 M
  • EBITDA $ -56 M
  • 60-Month Beta 0.76
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.08

Options Overview Details

View History
  • Implied Volatility 190.71% ( +61.79%)
  • Historical Volatility 95.24%
  • IV Percentile 67%
  • IV Rank 22.21%
  • IV High 807.51% on 03/27/24
  • IV Low 14.62% on 06/20/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 75
  • Volume Avg (30-Day) 467
  • Put/Call OI Ratio 0.03
  • Today's Open Interest 8,293
  • Open Int (30-Day) 4,849

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.31
  • Number of Estimates 4
  • High Estimate -0.16
  • Low Estimate -0.41
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -6.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.16 +26.90%
on 10/23/24
5.54 -27.62%
on 11/01/24
+0.85 (+26.70%)
since 10/22/24
3-Month
2.38 +68.84%
on 09/30/24
5.54 -27.62%
on 11/01/24
+1.06 (+35.93%)
since 08/22/24
52-Week
1.11 +261.29%
on 11/30/23
5.54 -27.62%
on 11/01/24
+2.85 (+245.69%)
since 11/22/23

Most Recent Stories

More News
Eledon Pharmaceuticals Announces Recent Business Highlights and Third Quarter 2024 Financial Results

ELDN : 4.01 (-1.47%)
Eledon Pharmaceuticals to Participate in Guggenheim Securities Inaugural Healthcare Innovation Conference

ELDN : 4.01 (-1.47%)
Eledon Pharmaceuticals Announces Pricing of $85 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

ELDN : 4.01 (-1.47%)
Eledon Pharmaceuticals Announces Positive Initial Data from Subjects with Type 1 Diabetes Treated with Tegoprubart as Part of an Immunosuppression Regimen Following Islet Transplantation in Investigator-Initiated Trial at UChicago Medicine

ELDN : 4.01 (-1.47%)
2 'Strong Buy'-Rated Stocks That Wall Street Believes Can Soar Over 360%

Analysts see enormous long-term potential in these two penny stocks.

ABOS : 2.37 (+2.60%)
ELDN : 4.01 (-1.47%)
$SPX : 5,969.34 (+0.35%)
2 Penny Stocks Wall Street Expects to Soar Over 400%

These two penny stock companies, while risky and volatile, have the potential to generate massive returns, according to Wall Street's price forecasts.

ABOS : 2.37 (+2.60%)
$SPX : 5,969.34 (+0.35%)
ELDN : 4.01 (-1.47%)
2 Penny Stocks That Wall Street Predicts Will Soar Over 300%

While these two penny stocks have the potential for exceptional returns, they also carry greater risk and volatility.

ELDN : 4.01 (-1.47%)
ABOS : 2.37 (+2.60%)
MRNA : 41.11 (+7.48%)
$SPX : 5,969.34 (+0.35%)
Lexaria Bioscience (NASDAQ: LEXX) Tracking Path to Drug Delivery Innovation, Commercialization

Lexaria Bioscience’s (NASDAQ: LEXX) path to becoming a global leader and innovator in drug delivery traces its origins to 2014, when CEO Chris Bunka redirected the company to its current business, focusing...

ELDN : 4.01 (-1.47%)
LEXX : 2.09 (-3.24%)
Lexaria Bioscience (NASDAQ: LEXX) Appoints New Board Member

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced an addition to its board of directors; the company named industry veteran Catherine Turkel, PharmD, PhD,...

AGN.AX : 0.720 (-0.69%)
LEXX : 2.09 (-3.24%)
ELDN : 4.01 (-1.47%)
ABBV : 176.95 (+3.04%)
Eledon Pharmaceuticals to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Management to host conference call and webcast at 4:30 pm ET IRVINE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”)...

ELDN : 4.01 (-1.47%)

Business Summary

Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune and neurodegenerative disease. Eledon Pharmaceuticals Inc., formerly known as Novus Therapeutics Inc., is based in IRVINE, Calif.

See More

Key Turning Points

3rd Resistance Point 4.38
2nd Resistance Point 4.28
1st Resistance Point 4.14
Last Price 4.01
1st Support Level 3.90
2nd Support Level 3.80
3rd Support Level 3.66

See More

52-Week High 5.54
Last Price 4.01
Fibonacci 61.8% 3.85
Fibonacci 50% 3.32
Fibonacci 38.2% 2.80
52-Week Low 1.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar